Enduro Genetics Secures $12.4M to Tackle Biomanufacturing Challenges and Expand Commercial Efforts

Copenhagen-based Enduro Genetics, a synthetic biology startup, announced it has raised $12.4 million in a Series A funding round led by Supernova Invest, NOON Ventures, and Sandwater. This latest investment brings the company’s total funding to $18.6 million, which includes grants from the BioInnovation Institute and the European Innovation Council accelerator.

The new capital will be directed toward scaling the company’s platform and accelerating the commercialization of its biomanufacturing solutions. CEO Christian Munch emphasized that the investment will support their goals of enhancing the technological foundation and expanding their applications within biopharmaceutical expression systems. He remarked, “The funding allows us to accelerate our commercialization efforts, strengthen our technology platform, and expand the technology for use in biopharmaceutical expression systems.”

Addressing Long-Standing Biomanufacturing Inefficiencies

Enduro Genetics is working to solve a long-standing problem that has hindered large-scale biomanufacturing: the productivity drop in industrial production processes. The global biomanufacturing market, valued at around $412 billion, spans critical sectors including industrial enzymes, biodegradable materials, alternative proteins, and pharmaceuticals. Despite advancements in genetic engineering, many industrial processes face setbacks due to the unstable nature of microbial production systems.

As large-scale production environments place stress on genetically engineered microorganisms, mutations arise, leading to “cell-to-cell variation.” This phenomenon occurs when cells prioritize survival over productivity, resulting in a proliferation of non-productive cells. Over time, these non-productive cells dominate the production system, reducing overall yields and diminishing efficiency.

Peter Rugbjerg, founder and CSO of Enduro Genetics, explained that the issue of cell variation has long been a barrier for industries and academic researchers. “Too many companies have been limited by the fact that only a minority of cells used in bioprocesses today contribute to high production. At Enduro, we’re redefining bioprocesses with a new optimization technology to unlock biotechnology’s full potential,” he stated.

The Synthetic Addiction Technology

Founded as a spin-off from the Technical University of Denmark, Enduro Genetics has developed a patented innovation known as “synthetic addiction.” This technology integrates a genetic plug-in into the microbial production host, linking cell growth and survival directly to production levels. As a result, only the cells that maintain high production can thrive, while non-productive cells are eliminated from the population.

By stabilizing the microbial environment, Enduro Genetics ensures consistent production rates, scalability, and cost-effective outcomes in biomanufacturing. The company is positioning this technology as a game-changer for industries transitioning to sustainable, bio-based products such as biofuels, bioplastics, specialty chemicals, and alternative proteins.

Enduro Genetics currently collaborates with key players in the biopharmaceutical, food, agriculture, and industrial sectors, leveraging its technology to improve production outcomes and address sustainability goals.